.jpeg)
{{ variable.name }}
In China, pazopanib was approved for marketing on March 3, 2017; the National Medical Products Administration (NMPA) approved pazopanib for the first-line treatment of patients with advanced renal cell carcinoma and patients with advanced renal cancer who have received cytokine therapy.
1. Generic name: pazopanib (pazopanib)
2. Trade name: VOTRIENT
It is used to treat patients with advanced renal cell carcinoma (RCC).
200mg, tablet.
1. Recommended dose: 800mg orally, once a day.
2. Taking time: Take on an empty stomach (1 hour before meals or 2 hours after meals).
3. Do not crush it for consumption (it may increase the absorption rate and affect the efficacy).
1. Hepatic insufficiency : reduce to 200mg/day for patients with moderate liver function impairment; contraindicated for patients with severe liver function impairment.
2. Drug interaction :
When strong CYP3A4 inhibitors (such as ketoconazole) are used together, reduce the dose to 400mg.
Concomitant use of strong CYP3A4 inducers (such as rifampicin) should be avoided.
3. Other adjustments : Adjust in steps of 200mg based on tolerance, with the maximum dose not exceeding 800mg.
1. Effect of diet : High-fat/low-fat diet will increase the blood concentration of the drug by 2 times, and it must be taken on an empty stomach.
2. Treatment of missed doses : If it is less than 12 hours before the next dose, skip it and do not take it again.
3. Vomiting treatment : If you vomit after taking the medicine, do not take more medicine. Take the medicine next time as originally planned.
4. before and after surgery: Stop medication for at least 7 days before surgery. The time to resume medication after surgery will be determined based on the wound healing condition.
1. Pregnant women : It can cause fetal damage and is contraindicated during pregnancy (pregnancy grade D).
2. Lactation : Suspend breastfeeding (it is unknown whether the drug enters the breast).
3. Children : safety has not been established.
4. Elderly : Patients aged ≥65 years old need to monitor liver function more closely.
1. Common (≥20%) : diarrhea, hypertension, hair discoloration, nausea, anorexia, vomiting.
2. Serious adverse reactions :
Hepatotoxicity (monitor ALT/AST), QT interval prolongation (monitor electrocardiogram), bleeding events (disabled for those with a history of bleeding within 6 months), arterial thrombosis (risk of myocardial infarction/stroke).
There are no absolute contraindications, but it is prohibited in the following situations:
1. Severe liver function damage.
2. History of cerebral hemorrhage/digestive tract bleeding within 6 months.
3. Pregnancy period.
1. CYP3A4 inhibitor : Avoid combined use of strong inhibitors (such as clarithromycin).
2. CYP3A4 inducer : Avoid combined use of strong inducers (such as rifampicin).
3. Narrow therapeutic window drug : Avoid combined use of drugs metabolized by CYP3A4/2D6/2C8 (such as warfarin).
It is not clearly stated. It is recommended to store it according to the conventional oral tablets (avoid light, in a cool and dry place).